Pharmacotherapy of benign prostatic hyperplasia: Inhibitor of 5 alpha- reductase

International Urology and Nephrology

Volumn 29, Issue 3, 1997, Pages 323-330

  Polat, O ^a   Ozbey I ^a   Gul O ^a   Demirel, A ^a   Bayraktar, Y ^a  

^a ATATURK UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

FINASTERIDE; STEROID 5ALPHA REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; TESTOSTERONE METABOLISM;

EID: 0030748931     PISSN: 03011623     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02550930     Document Type: Article

References (18)

1. McConnel, J. D.: Androgen ablation and blockade in the treatment of benign prostatic hyperplasia. Urol. Clin. North. Am., 17,661 (1990).
2. Lepor, H., Shapiro, E.: This month in investigative urology: Alpha-adrenergic innervation of the prostate: Insights into pharmacotherapy of BPH. J. Urol., 143, 590 (1990).
3. Lepor, H.: Nonoperative management of benign prostatic hyperplasia. J. Urol., 141, 1283 (1989).
4. Vermeulen, A.: Hormonal effects of an orally active 4-azasteroid inhibitor of 5 alpha-reductase in humans. Prostate, 14, 45 (1989).
5. Barry, M. J., Fowler, F. J., O'Leary, M. P.: Correlation of the American Urological Association symptom index with self-administered versions of the Madsen-Iversen, Boyarsky, and Maine Medical Assessment program symptom index. J. Urol., 148, 1558 (1992).
6. Caine, M.: The present role of alpha-adrenergic blockers in the treatment of benign prostatic hypertrophy. J. Urol., 136, 1 (1986).
7. McNeal, J. E.: Normal histology of the prostate. Am. J. Surg. Pathol., 12, 619 (1988)
8. McNeal, J. E.: Pathology of benign prostatic hyperplasia. Urol. Clin. North. Am., 17, 477 (1990).
9. Hald, T.: Urodynamics in benign prostatic hyperplasia: A survey. Prostate, 2 (Suppl.), 69 (1989).
10. Peters, C. A., Walsh, P. C.: The effect of nafarelin acetate, a luteinizing-hormone releasing hormone agonist, on benign prostatic hyperplasia. N. Engl. J. Med., 317, 599 (1987).
11. Lepor, H., Machi, G.: The relative efficacy of terazosin versus terazosin and flutamide for the treatment of symptomatic BPH. Prostate, 20, 89 (1992).
12. Gormley, G. J., Stoner, E., Bruskewitz, R. C., for the Finasteride Study Group: The effect of finasteride in men with benign prostatic hyperplasia. N. Engl. J. Med., 327, 1185 (1992).
13. Finasteride Study Group. Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. Prostate. 22, 291 (1993).
14. Gormley, G. J., Cook, T.: Effect of finasteride on prostate-specific antigen density. Urology, 43, 1 (1994).
15. Tchetgen, M. B., Oesterling, J. E.: The role of prostate-specific antigen in evaluation of benign prostatic hyperplasia. Urol. Clin. North. Am., 22, 335 (1995).
16. Rittmaster, R. S., Stoner, E., Thompson, D. L.: Effect of MK-906, a specific 5 alpha-reductase inhibitor, on serum androgens and androgen conjugates in normal men. J. Androl., 10, 259 (1989).
17. Vermeulen, A., Giagulli, V. A., Schepper, P. D.: Hormonal effects of an orally active 4-azasteroid inhibitor of 5 alpha-reductase in humans. Prostate, 14, 45 (1989).
18. Stoner, E., the Finasteride Study Group. Maintenance of clinical efficacy with finasteride therapy for 24 months in patients with benign prostatic hyperplasia. Arch. Intern. Med., 17, 338 (1994).